A STUDY OF THERAPEUTIC RESPONSE AND ADVERSE EFFECTS OF INTRAVENOUS ERYTHROPOIETIN VERSUS SUBCUTANEOUS ERYTHROPOIETIN ON HEMODIALYSIS PATIENTS IN THE DEPARTMENT OF NEPHROLOGY OF OHRC
Objective: To study the efficacy of intravenous erythropoietin and subcutaneous erythropoietin in hemodialysis patients who have persistent anemia despite correction of iron therapy and to measure the outcomes in terms of raise in haemoglobin concentration and adverse events in both the groups.
Methods: After ethical committee approval the current study was conducted at the Department of Hemodialysis of Owasi Hospital and Research Centre, Hyderabad a period of 6 mo duration. 60 patients undergoing hemodialysis were recruited into out study who had haemoglobin less than 10.0 despite corrected iron levels. Patients were divided into two groups for intravenous administration and subcutaneous administration of alpha erythropoietin. Patients were stratified into three sub-groups of mild, moderate and severe anaemia. Therapeutic response was recorded in the form of monthly hemoglobin and hemoatocrit. Of the 30 patients in the subcutaneous group, erythropoietin was given to 19 males and 11 females, while intravenous erythropoietin was administered to 17 males and 13 females in the other 30 patients.
Results: The mean hemoglobin level in the subcutaneous group was 5.16 at the commencement of the study and in the intravenous group the mean hemoglobin was 5.0. In the subcutaneous group, the mean rise in the hemoglobin was rapidly achieved in 3 mo duration when compared to the intravenous group. Mean Systolic Blood pressure was higher in the intravenous group when compared to the subcutaneous group. Spillage of the drug was minimal in subcutaneous group when compared to the intravenous group.
Conclusion: After correction of the iron deficiency, low dose of erythropoietin subcutaneously promised to maintain expected hemoglobin level above 10 g/dL with no adverse events compared to intravenous erythropoietin. Erythropoitin alpha at a dose of 4000 IU was enough to achieve the therapeutic target of Hemoglobin>10.0 by administering subcutaneously accelerated hypertension was less when compared to Intravenous erythropieitn post dialysis. Hence we recommend to use erythropoietin subcutaneously rather than intravenously.
2. Kidney Disease: Improving global outcomes (KDIGO) anemia work group: kdigo clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl 2012;2:279-335.
3. KDOQI. Clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2001 update of hemoglobin target. Am J Kidney Dis 2007;50:471-530.
4. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. N Engl J Med 1987; 316:73-8.
5. Dmitrieva O, de Lusignan S, Macdougall IC. Association of anaemia in primary care patients with chronic kidney disease: a cross-sectional study of quality improvement in chronic kidney disease (QICKD) trial data. BMC Nephrol 2013;14:24.
6. World Kidney day: Chronic Kidney Disease. Global facts about kidney disease; 2015.
7. Couser WG, Remuzzi G, Mendis S, Tonelli M. The contributions of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int Dec 2011;80:1258-70.
8. Pharmacotherapy-A Pathophysiologic approach. 8th edition. Joseph T. Dipiro, Robert L. Talbert; 2011. p. 798-804.
9. K/DOQI Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults. Am J Kidney Dis 2006;47(Suppl 3):S11-S145.
10. PG Barclay, ER Fischer, DC Harris. Interpatient variation in response to subcutaneous versus intravenous low dose erythropoietin. Clin Nephrol 1993;40:277-80.
11. Donald S Silverberg, Dov Wexler, Miriam Blum, Joseph Z Tchebiner, David Sheps. The effect of correction of anaemia in diabetics and nondiabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dialysis Transplantation 2003;18:141-6.
12. Besarab A, Reyes CM, Hornberger J. Meta-analysis of subcutaneous versus intravenous epoetin in the maintenance treatment of anemia in hemodialysis patients. Am J Kidney Dis 2002;40:439-46.
13. James S Kaufman, Domentic J Reda, Carill Fye, David S Goldfarb. Department of the veterans affairs cooperative study group on erythropoietin in hemodialysis patients. N Engl J Med 1998;339:578-83.